This company has been marked as potentially delisted and may not be actively trading. Stellar Biotechnologies (SBOT) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock SBOT vs. GLSI, LRMR, ZNTL, ACTU, OGI, SAVA, DERM, TELO, GNLX, and NLTXShould you be buying Stellar Biotechnologies stock or one of its competitors? The main competitors of Stellar Biotechnologies include Greenwich LifeSciences (GLSI), Larimar Therapeutics (LRMR), Zentalis Pharmaceuticals (ZNTL), Actuate Therapeutics (ACTU), Organigram (OGI), Cassava Sciences (SAVA), Journey Medical (DERM), Telomir Pharmaceuticals (TELO), Genelux (GNLX), and Neoleukin Therapeutics (NLTX). These companies are all part of the "medical" sector. Stellar Biotechnologies vs. Greenwich LifeSciences Larimar Therapeutics Zentalis Pharmaceuticals Actuate Therapeutics Organigram Cassava Sciences Journey Medical Telomir Pharmaceuticals Genelux Neoleukin Therapeutics Greenwich LifeSciences (NASDAQ:GLSI) and Stellar Biotechnologies (NASDAQ:SBOT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, community ranking, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations. Is GLSI or SBOT more profitable? Greenwich LifeSciences has a net margin of 0.00% compared to Stellar Biotechnologies' net margin of -1,782.64%. Stellar Biotechnologies' return on equity of -51.12% beat Greenwich LifeSciences' return on equity.Company Net Margins Return on Equity Return on Assets Greenwich LifeSciencesN/A -185.12% -164.27% Stellar Biotechnologies -1,782.64%-51.12%-48.37% Does the MarketBeat Community prefer GLSI or SBOT? Stellar Biotechnologies received 226 more outperform votes than Greenwich LifeSciences when rated by MarketBeat users. Likewise, 66.48% of users gave Stellar Biotechnologies an outperform vote while only 44.44% of users gave Greenwich LifeSciences an outperform vote. CompanyUnderperformOutperformGreenwich LifeSciencesOutperform Votes844.44% Underperform Votes1055.56% Stellar BiotechnologiesOutperform Votes23466.48% Underperform Votes11833.52% Which has higher valuation and earnings, GLSI or SBOT? Stellar Biotechnologies has higher revenue and earnings than Greenwich LifeSciences. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Stellar Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGreenwich LifeSciencesN/AN/A-$8.89M-$0.80-11.69Stellar Biotechnologies$210K143.91-$5.03M-$1.76-3.22 Does the media prefer GLSI or SBOT? In the previous week, Greenwich LifeSciences had 5 more articles in the media than Stellar Biotechnologies. MarketBeat recorded 5 mentions for Greenwich LifeSciences and 0 mentions for Stellar Biotechnologies. Stellar Biotechnologies' average media sentiment score of 0.00 beat Greenwich LifeSciences' score of -0.03 indicating that Stellar Biotechnologies is being referred to more favorably in the news media. Company Overall Sentiment Greenwich LifeSciences Neutral Stellar Biotechnologies Neutral Do analysts recommend GLSI or SBOT? Greenwich LifeSciences currently has a consensus target price of $38.00, suggesting a potential upside of 306.42%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, analysts plainly believe Greenwich LifeSciences is more favorable than Stellar Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greenwich LifeSciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Stellar Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals believe in GLSI or SBOT? 4.2% of Greenwich LifeSciences shares are held by institutional investors. Comparatively, 1.7% of Stellar Biotechnologies shares are held by institutional investors. 51.7% of Greenwich LifeSciences shares are held by insiders. Comparatively, 7.8% of Stellar Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryGreenwich LifeSciences and Stellar Biotechnologies tied by winning 8 of the 16 factors compared between the two stocks. Remove Ads Get Stellar Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for SBOT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SBOT vs. The Competition Export to ExcelMetricStellar BiotechnologiesPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.22M$6.77B$5.58B$7.92BDividend YieldN/A2.80%5.35%4.04%P/E Ratio-3.227.1123.1218.81Price / Sales143.91205.89369.1988.69Price / CashN/A65.6738.1634.64Price / Book2.676.146.704.18Net Income-$5.03M$142.11M$3.20B$247.10M Stellar Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SBOTStellar BiotechnologiesN/A$5.67-1.4%N/A+17.3%$30.22M$210,000.00-3.2225GLSIGreenwich LifeSciences1.8215 of 5 stars$11.25+1.3%$38.00+237.8%-51.4%$147.88MN/A-14.063News CoverageGap UpLRMRLarimar Therapeutics1.9562 of 5 stars$2.28-10.2%$20.13+782.7%-73.2%$145.48MN/A-1.9830High Trading VolumeZNTLZentalis Pharmaceuticals1.8853 of 5 stars$1.98+3.7%$8.24+316.4%-91.4%$141.11M$40.56M-0.80160Earnings ReportAnalyst RevisionNews CoverageGap DownACTUActuate TherapeuticsN/A$7.20+6.7%$20.00+177.8%N/A$140.63MN/A0.0010OGIOrganigram0.5665 of 5 stars$1.11flatN/A-49.5%$140.10M$166.12M-2.92860News CoverageSAVACassava Sciences3.9111 of 5 stars$2.80-1.4%$111.50+3,882.1%-93.2%$137.20MN/A-2.0330Short Interest ↓DERMJourney Medical2.5149 of 5 stars$6.54+13.9%$9.67+47.8%+80.4%$136.62M$57.77M-6.9690Earnings ReportAnalyst RevisionGap DownHigh Trading VolumeTELOTelomir Pharmaceuticals2.1652 of 5 stars$4.53-0.7%$15.00+231.1%-49.8%$134.83MN/A-7.811Gap UpGNLXGenelux1.4008 of 5 stars$3.89-1.0%$18.25+369.2%-50.4%$134.35M$8,000.00-4.0910Earnings ReportUpcoming EarningsAnalyst ForecastNLTXNeoleukin TherapeuticsN/A$14.21-6.7%N/A-75.0%$133.55MN/A-4.5790High Trading Volume Remove Ads Related Companies and Tools Related Companies GLSI Competitors LRMR Competitors ZNTL Competitors ACTU Competitors OGI Competitors SAVA Competitors DERM Competitors TELO Competitors GNLX Competitors NLTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SBOT) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredTrump’s betrayal exposed Fair warning: this will not make for easy viewing. Especially if you voted for Trump, put your faith in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stellar Biotechnologies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Stellar Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SBOT Stock Free SBOT Stock Alerts